Global Market Pulse: Mixed Signals as US Futures Diverge, Asia Surges

Unknown Apr 02, 2026 600 Views

Today's Market at 08:35am US Market (Futures) Nasdaq = 71.50 Dow Jones = -87.50 S&P 500 = -14.40 European (Futures) Ftse 100 = +65.20 Cac 40 = -24.50 &n...

Today's Market at 08:35am

US Market (Futures)

Nasdaq = 71.50

Dow Jones = -87.50

S&P 500 = -14.40

European (Futures)

Ftse 100 = +65.20

Cac 40 = -24.50

Dax = -36.50

Asian

Nikkei 225 = +574.48

ASX 200 = +4.00

Straits Times = +39.57

Hang Seng = +415.43

KOSPI = +5.59

Taiwan weighted = +105.16

China A50 = +4.28

Gift Nifty = 22739 (+131.00)

FII and DII Trading Activity for March 17, 2025 in Cash market:

FIIs: Net Sell of ₹4488.45 crore

DIIs: Net Buy of ₹6000.60 crore

Several key stocks are in focus as the Indian markets open on March 18, 2025:

- Bajaj Finserv has signed agreements to acquire Allianz SE's 26% stake in their insurance joint ventures for approximately €2.6 billion.

- IndusInd Bank faces a potential downgrade as Moody's places its Baseline Credit Assessment under review.

- Vedanta's chairman, Anil Agarwal, expressed optimism about the company's demerged entities, stating each has the potential to become a $100 billion enterprise.

- Tata Motors announced a price hike of up to 2% on its commercial vehicles, effective April 1, citing rising input costs.

- IREDA has increased its borrowing limit by Rs 5,000 crore for FY 2024-25.

- Hindustan Unilever received approval from the Competition Commission of India to acquire beauty brand Minimalist's parent company.

- IRCON International secured a Rs 1,096 crore contract from the Meghalaya government.

- Coffee Day Enterprises reached a settlement to clear Rs 205 crore in outstanding debt.

The India stock market is expected to open on a positive note, with a strong close by the US Markets overnight and Asian markets & GIFT Nifty are leading from the front.

Stocks in F&O ban

BSE, Indusind Bank, Hindustan Copper, Manappuram Finance, SAIL

Source: NDTV, Investing.com, NSE India

Stay Ahead – Explore Now! Concord Biotech Secures USFDA Approval for Generic Tofacitinib Tablets